Limited Coverage Drugs – risedronate

Generic  name	Strength, form	Special Authority criteria	Approval period
risedronate	5 mg tablet or 35 mg tablet	Clinical or radiographically documented fracture due to osteoporosis OR Glucocorticoid-induced osteoporosis in patients who are receiving or expected to receive the equivalent dose of 7.5 mg or more of prednisone per day for 90 or more consecutive days	Indefinite     1 year
risedronate	30 mg	Diagnosis of Paget's disease	Indefinite

 Practitioner exemptions

• None

Special notes

• Patients who meet the above criteria for osteoporosis for risedronate automatically receive coverage for both alendronate and risedronate.
• Clinical fracture is defined as a symptomatic (painful) fracture.
• Radiographically documented fracture is defined as a fracture identified by x-ray (e.g., vertebral compression fracture). This may be asymptomatic.
• Coverage is intended for patients taking glucocorticoids with significant systemic absorption only (i.e., by oral or parenteral routes).

Special Authority requests

• Log in to eForms​
• HLTH 5328 - Special Authority Request (PDF, 523KB)